Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 USD | -1.09% | -3.20% | +26.39% |
04-23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
04-10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Sales 2024 * | 72K 5.74M | Sales 2025 * | 72K 5.74M | Capitalization | 5.23M 417M |
---|---|---|---|---|---|
Net income 2024 * | -4M -319M | Net income 2025 * | -8M -638M | EV / Sales 2024 * | 72.7 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 72.7 x |
P/E ratio 2024 * |
-3.29
x | P/E ratio 2025 * |
-2.63
x | Employees | 3 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.01% |
1 day | +0.13% | ||
1 week | -2.13% | ||
Current month | +0.13% | ||
1 month | -3.16% | ||
3 months | +17.20% | ||
6 months | +26.02% | ||
Current year | +27.78% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 12/07/10 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 26/09/22 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 31/08/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 12/07/10 |
Wayne Linsley
BRD | Director/Board Member | 67 | 15/01/20 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 30/09/20 |
Date | Price | Change | Volume |
---|---|---|---|
02/05/24 | 1.82 | -1.09% | 4 486 |
01/05/24 | 1.84 | +0.13% | 10,991 |
30/04/24 | 1.838 | -2.77% | 36,328 |
29/04/24 | 1.89 | +2.16% | 39,285 |
26/04/24 | 1.85 | -1.60% | 55,867 |
Delayed Quote Nasdaq, May 01, 2024 at 09:30 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+27.78% | 5.23M | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+55.13% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.74% | 8.84B | |
-1.87% | 7.93B |
- Stock Market
- Equities
- SILO Stock